Figures & data
Table 1 Categorization of treatment regimens
Figure 1 Flowchart of the study cohorts of patients with primary refractory or relapsed DLBCL in the LYFO database in Denmark, 2000–2015.
Abbreviations: CNS, central nervous system; DLBCL, diffuse large B-cell lymphoma.
Table 2 Baseline characteristics of the 1,228 patients with primary refractory or relapsed diffuse large B-cell lymphoma in the LYFO database in Denmark, 2000–2015, by treatment category
Table 3 Adjusted ORs (with accompanying 95% CIs) for the choice of treatment-intensity (non-salvage vs no/palliative and salvage vs non-salvage) for the total cohort, and the subgroup of 610 patients with relapsed disease in the LYFO database in Denmark, 2000–2015
Table 4 Baseline characteristics of the 277 patients with refractory or relapsed DLBCL previously treated with rituximab and receiving treatment for relapsed disease in the LYFO database in Denmark, 2000–2015
Figure 2 Survival of patients with primary refractory or relapsed diffuse large B-cell lymphoma previously exposed to rituximab according to relapse regimens in the LYFO database in Denmark, n=277.
Table 5 Adjusted HRs and 5-year OS rates (with accompanying CIs) for the 277 patients with refractory or relapsed DLBCL previously treated with rituximab who received relapse treatment in the LYFO database in Denmark, 2000–2015